Previous 10 | Next 10 |
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare dise...
AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 11:30 a.m. ET on Thursday, ...
AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing a pipeline of six gene-therapeutics covering Fabry's disease (AVR-RD-01), Gau...
AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise. If successful, it is looking at a multibillion dollar market. For further details see: AVROBIO: Undercovered Gene Therapy De...
Gainers: Kaixin Auto (KXIN) +104%.FTS International (FTSI) +44%.Ayro (AYRO) +42%.Blink Charging (BLNK) +31%.Dada Nexus (DADA) +30%.Ideanomics (IDEX) +23%.Ra Medical Systems (RMED) +22%.SPI Energy (SPI) +21%.Canaan (CAN) +20%.Longview Acquisition (LGVW) +20%.Losers: Tantech (TAN...
Gainers: Titan Pharmaceuticals (TTNP) +31%, Idera Pharmaceuticals (IDRA) +27%, Mesoblast (MESO) +20%, 22nd Century Group (XXII) +14%, Genfit (GNFT) +13%.Losers: AVROBIO (AVRO) -14%, Stealth BioTherapeutics (MITO) -14%, Kazia Therapeu...
Avrobio (AVRO) has priced its public offering of 5M common shares at $15.00/share, for gross proceeds of ~$75M.Underwriters' over-allotment is an additional 750K shares. Net proceeds will be used to fund programs in Fabry disease, cystinosis, Gaucher disease type 1, Hunter syndrome, Pompe dis...
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds from the underwritten public offering will t...
AVROBIO (AVRO) intends to offer $75M of its common stock in an underwritten public offering. Underwriters have an option to purchase up to $11.25M of additional shares.Number of shares are price are yet to be determined. For further details see: AVROBIO readies $75M equity offering
Avrobio (AVRO) announces positive data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis. New clinical updates announced today include:AVR-RD-02 for Gaucher disease type 1: Positive early reductions in plasma lyso-Gb1 and chitotriosidase activity at three mo...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 09:02:05 ET AvroBio Inc (AVRO) announced stock split at a ratio of 1-for-12 on 2024-06-21 ... Full story available on KlickAnalytics.com
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...